Lyra Therapeutics subleases ~23,704 sq ft lab/office in Waltham, MA

Lyra Therapeutics, Inc.

Sublease with RVAC Medicines for 23,704 sq ft at 880 Winter Street, Waltham, MA.
Term expected to start Jan 1, 2024; expires Nov 30, 2032.
Monthly base rent $150,125.33 (~$1.8M annual); 3% annual escalator; first two months rent-free.
Requires $450,375.99 letter of credit as security deposit; also pays share of operating expenses, utilities, taxes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lyra Therapeutics, Inc. entered into Sublease with RVAC Medicines (US), Inc. valued at $1,801,503.96 (effective 2023-12-21).

Action: entry
Agreement: lease
Counterparty: RVAC Medicines (US), Inc.
Value: $1,801,503.96
Effective: 2023-12-21

Exact text from the filing

On December 21, 2023, Lyra Therapeutics, Inc. (the “Company”) entered into a sublease agreement (the “Sublease”) with RVAC Medicines (US), Inc., a Delaware corporation (the “Sublessor”), for approximately 23,704 square feet of laboratory and office space at 880 Winter Street in Waltham, Massachusetts (the “Premises”).

View on SEC.gov

Browse all material agreements →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-073432

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.